- Current report filing (8-K)
26 5월 2009 - 9:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May 26,
2009
ALLOS THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
|
|
|
Westminster, Colorado
|
|
80020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Section 8 Other Events
Item 8.01 Other
Events.
On May 26, 2009, Allos
Therapeutics, Inc., a Delaware corporation (the Company), issued a press
release announcing that (a) the U.S. Food and Drug Administration (the FDA)
has accepted for filing the Companys New Drug Application (NDA) for
pralatrexate for the treatment of patients with relapsed or refractory
peripheral T-cell lymphoma, and (b) the FDA has granted the NDA priority
review status.
The press release
is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
99.1
|
Press
Release, dated May 26, 2009, entitled Allos Therapeutics Announces FDA
Accepts Pralatrexate NDA for Filing and Grants the Application Priority
Review Status.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: May 26,
2009
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
David C. Clark
|
|
|
David
C. Clark
|
|
Its:
|
Vice
President, Finance, Treasurer and Assistant Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated May 26, 2009, entitled Allos Therapeutics Announces FDA
Accepts Pralatrexate NDA for Filing and Grants the Application Priority
Review Status.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024